Blue Owl Capital has sharply reduced the value of its loans to specialty materials manufacturer Loparex, highlighting renewed concerns over credit quality and valuation practices across the $1.8tn private credit market, according to a report by Bloomberg.
Blue Owl’s flagship public business development company, OBDC, moved its exposure to Loparex to non-accrual status following the second quarter, reflecting uncertainty over whether investors will ultimately recover the full value of their loans...
Continue Reading
Sign up for FREE to read the full article and access 165K+ alternative investment headlines.